Endocannabinoids and Metabolic Disorders.

Blandine Gatta-Cherifi, Daniela Cota
Handbook of Experimental Pharmacology. 2015-01-01; : 367-391
DOI: 10.1007/978-3-319-20825-1_13

PubMed
Lire sur PubMed



1. Handb Exp Pharmacol. 2015;231:367-91. doi: 10.1007/978-3-319-20825-1_13.

Endocannabinoids and Metabolic Disorders.

Gatta-Cherifi B(1)(2)(3), Cota D(4)(5).

Author information:
(1)INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale,
U862, 33000, Bordeaux, France. .
(2)University of Bordeaux, Neurocentre Magendie, Physiopathologie de la
Plasticité Neuronale, U862, 33000, Bordeaux, France.
.
(3)Endocrinology Department, Haut-Lévêque Hospital, 33607, Pessac, France.
.
(4)INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale,
U862, 33000, Bordeaux, France. .
(5)University of Bordeaux, Neurocentre Magendie, Physiopathologie de la
Plasticité Neuronale, U862, 33000, Bordeaux, France. .

The endocannabinoid system (ECS) is known to exert regulatory control on
essentially every aspect related to the search for, and the intake, metabolism
and storage of calories, and consequently it represents a potential
pharmacotherapeutic target for obesity, diabetes and eating disorders. While the
clinical use of the first generation of cannabinoid type 1 (CB(1)) receptor
blockers has been halted due to the psychiatric side effects that their use
occasioned, recent research in animals and humans has provided new knowledge on
the mechanisms of actions of the ECS in the regulation of eating behavior, energy
balance, and metabolism. In this review, we discuss these recent advances and how
they may allow targeting the ECS in a more specific and selective manner for the
future development of therapies against obesity, metabolic syndrome, and eating
disorders.

DOI: 10.1007/978-3-319-20825-1_13
PMID: 26408168 [Indexed for MEDLINE]


Auteurs Bordeaux Neurocampus